HKEX

XPENG announces dealer partnerships in UAE, Egypt, Azerbaijan, Jordan and Lebanon

Retrieved on: 
Thursday, February 22, 2024
EVS, XPeng, EV, G9, XPEV, G6, GM, Globalization, HKEX, Ali, Partnership, Drug

XPENG, a leading Chinese smart electric vehicle company, announces dealer partnerships in UAE, Egypt, Azerbaijan, Jordan and Lebanon.

Key Points: 
  • XPENG, a leading Chinese smart electric vehicle company, announces dealer partnerships in UAE, Egypt, Azerbaijan, Jordan and Lebanon.
  • Through the partnerships, XPENG will bring its EVs to local consumers within each region with branded showrooms and start-to-end customer support throughout the buying process.
  • The partnerships mark several "firsts" for XPENG on its road to globalisation as it aspires to become a leading player in the EV sector.
  • This year, XPENG will start delivering these vehicles in Jordan and Lebanon from Q2, and in Egypt from Q3.

Bilibili Inc. to Report Fourth Quarter and Fiscal Year 2023 Unaudited Financial Results on Thursday, March 7, 2024

Retrieved on: 
Tuesday, February 20, 2024
PIN, Webcast, HKEX

SHANGHAI, China, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Bilibili Inc. (“Bilibili” or the “Company”) (NASDAQ: BILI and HKEX: 9626), an iconic brand and a leading video community for young generations in China, today announced that it will report its fourth quarter and fiscal year 2023 unaudited financial results on Thursday, March 7, 2024, before the open of U.S. markets.

Key Points: 
  • SHANGHAI, China, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Bilibili Inc. (“Bilibili” or the “Company”) (NASDAQ: BILI and HKEX: 9626), an iconic brand and a leading video community for young generations in China, today announced that it will report its fourth quarter and fiscal year 2023 unaudited financial results on Thursday, March 7, 2024, before the open of U.S. markets.
  • The Company’s management will host an earnings conference call at 7:00 AM U.S. Eastern Time on March 7, 2024 (8:00 PM Beijing/Hong Kong Time on March 7, 2024).
  • Details for the conference call are as follows:
    All participants must use the link provided above to complete the online registration process in advance of the conference call.
  • Upon registering, each participant will receive a set of participant dial-in numbers and a personal PIN, which will be used to join the conference call.

Bilibili Inc. Announces Repurchase Right Notification for 1.375% Convertible Senior Notes due 2026

Retrieved on: 
Tuesday, February 20, 2024
FICC, Note, Repurchase agreement, NOTES, Depository Trust Company, Mechanics, Exercise, Debt-to-GDP ratio, HKEX, Trustee, CUSIP, PARTIES, Security (finance)

The Repurchase Right entitles each holder of the Notes to require the Company to repurchase all of such holder’s Notes, or any portion thereof that is an integral multiple of US$1,000 principal amount.

Key Points: 
  • The Repurchase Right entitles each holder of the Notes to require the Company to repurchase all of such holder’s Notes, or any portion thereof that is an integral multiple of US$1,000 principal amount.
  • If all outstanding Notes are surrendered for repurchase through exercise of the Repurchase Right, the aggregate cash purchase price will be US$429,343,000.
  • In order to exercise the Repurchase Right, a holder must follow the transmittal procedures set forth in the Company’s Repurchase Right Notice to holders (the “Repurchase Right Notice”), which is available through the Depository Trust Company and Deutsche Bank Trust Company Americas.
  • If a holder has tendered any Notes pursuant to the Repurchase Right, such Notes cannot be converted unless the holder withdraws the tender in accordance with the terms of the Indenture.

Zai Lab Announces Participation in March Investor Conference

Retrieved on: 
Wednesday, March 6, 2024
Research, Infectious Diseases, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Zai, HKEX

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conference in March 2024:

Key Points: 
  • Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conference in March 2024:
    A live webcast of the presentation will be available on the Investor Relations page of Zai Lab’s website at ir.zailaboratory.com/webcasts-presentations and an archived replay will be available for up to 90 days following the completion of the event.

Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)

Retrieved on: 
Wednesday, March 6, 2024
Biotechnology, Other Health, Health, General Health, Women, Pharmaceutical, Oncology, Research, Consumer, Science, Clinical Trials, Progression-free survival, Fudan University, Shanghai Cancer Center, ISD, PARP, ESGO, BRCA, HKEX, Platelet, OS, Gynecologic Oncology (journal), Ovarian cancer, SGO, Patient, Congress, Development, Niraparib, Pharmaceutical industry

“Previous progression-free survival and interim OS data from the NORA study demonstrated the benefit of niraparib maintenance therapy with an individualized starting dose among Chinese patients with PSROC,” said Dr. Rafael Amado, President, Head of Global Oncology Research and Development, Zai Lab.

Key Points: 
  • “Previous progression-free survival and interim OS data from the NORA study demonstrated the benefit of niraparib maintenance therapy with an individualized starting dose among Chinese patients with PSROC,” said Dr. Rafael Amado, President, Head of Global Oncology Research and Development, Zai Lab.
  • “We look forward to sharing the final OS findings from this study at both the 2024 ESGO and SGO conferences.
  • The final OS analysis was conducted after ≥ 50% of OS events occurred in the intent-to-treat population.
  • No new safety signals were identified during the long-term follow up period subsequent to the primary analysis.

AnHeart Therapeutics and Innovent Announce China’s NMPA has Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer

Retrieved on: 
Tuesday, March 5, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, NSCLC, Ophthalmology, Senior, New Drug Application, MD, ROS1, HKEX, Patient, CDE, Medicine, ELCC, NDA, NMPA, TKI, Cancer, Priority review, Pharmaceutical industry

This NDA is for taletrectinib as a first-line treatment for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have not previously been treated with ROS1 TKIs.

Key Points: 
  • This NDA is for taletrectinib as a first-line treatment for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have not previously been treated with ROS1 TKIs.
  • In 2023, China’s NMPA accepted taletrectinib’s first NDA and granted Priority Review Designation for adult patients with locally advanced or metastatic ROS1-positive NSCLC who have been previously treated with ROS1 TKIs.
  • Both NDAs in China are based on positive results from the Phase 2 TRUST-I (NCT04395677) trial.
  • “I am pleased this second NDA for taletrectinib has been accepted in China.

Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis

Retrieved on: 
Monday, February 26, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Week, UPCR, HKEX, CRR, Safety, Patient, Lupus nephritis, Clinical trial, CDE, IND, KZR, NMPA, Kidney failure, Pharmaceutical industry

Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (Nasdaq: KZR) announced today that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) approved Kezar’s investigational new drug (IND) application for initiation of the Phase 2b PALIZADE trial in China of zetomipzomib in patients with lupus nephritis (LN).

Key Points: 
  • Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (Nasdaq: KZR) announced today that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) approved Kezar’s investigational new drug (IND) application for initiation of the Phase 2b PALIZADE trial in China of zetomipzomib in patients with lupus nephritis (LN).
  • Everest will join Kezar and enroll patients in China as part of the ongoing PALIZADE trial, a global, placebo-controlled Phase 2b clinical trial evaluating the efficacy and safety of two dose levels of zetomipzomib or placebo in patients with active LN.
  • In September 2023, Everest obtained exclusive rights to develop and commercialize zetomipzomib in Greater China, South Korea and Southeast Asia.
  • “With the approval of the zetomipzomib IND in China, Everest now has three medicines in the renal space either commercialized or in clinical development.

Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement

Retrieved on: 
Tuesday, February 20, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Therapy, Gilead Sciences, Drug development, Medication, HKEX, Antibody, Pharmaceutical industry

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announces an antibody evaluation and option agreement with Gilead Sciences, Inc.

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announces an antibody evaluation and option agreement with Gilead Sciences, Inc.
  • The agreement provides Gilead access to Biocytogen’s extensive fully human antibody library generated against a wide range of therapeutic targets.
  • Under the terms of the agreement, Biocytogen will receive a payment to enable Gilead’s evaluation of certain antibodies directed to a given nominated target.
  • Dr. Yuelei Shen, President and CEO of Biocytogen, said, “We are thrilled to collaborate with Gilead, a partner renowned for their drug development and commercialization expertise.

Baidu Launches China's First 24/7 Robotaxi Service

Retrieved on: 
Friday, March 8, 2024
Apollo, AI, Transport, Female, Airport, Yangtze, HKEX, Robotaxi, City, Beijing Daxing International Airport, BIDU, International Women's Day, Yangsigang Yangtze River Bridge, Rail transport

In Feb 2024, Baidu was approved for robotaxi pilot operation on highways to Beijing Daxing Airport, making Beijing the world's first capital city to launch airport robotaxi service.

Key Points: 
  • In Feb 2024, Baidu was approved for robotaxi pilot operation on highways to Beijing Daxing Airport, making Beijing the world's first capital city to launch airport robotaxi service.
  • In the same month, Baidu also launched fully driverless service across the Yangtze River in Wuhan, demonstrating its technical sophistication in navigating challenging geographic landscapes.
  • Apollo Go is now offering 24/7 autonomous driving service in selected areas of Wuhan, becoming China's first provider to offer such service.
  • On February 23, 2024, Apollo Go unveiled a similar service in Beijing, as Baidu was approved for robotaxi pilot operation on highways to Beijing Daxing Airport.

Alibaba Releases Report on Cross-Border Trade's Positive Impact on the U.S. Economy

Retrieved on: 
Wednesday, March 6, 2024
RMB, HKD, Computer, Growth, Alibaba Group, Electronics, Sale, HKEX, Electron capture, GDP, Care, NDP, BABA, Employment, Gross domestic product, Online shopping

NEW YORK, March 6, 2024 /PRNewswire/ -- Alibaba Group Holding Limited (NYSE: BABA and HKEX: 9988 (HKD Counter) and 89988 (RMB Counter), "Alibaba" or "Alibaba Group")  recently announced findings from a new report highlighting Alibaba's positive impact on the U.S. economy and how its e-commerce platforms support U.S. businesses. The report reflects positive growth in both retail sales and employment numbers in the U.S. resulting from the sale of American products to Chinese consumers through Alibaba's range of online marketplaces and platforms.

Key Points: 
  • New report quantifies the positive economic impacts of cross-border trade conducted by businesses leveraging Alibaba platforms, tools and solutions
    NEW YORK, March 6, 2024 /PRNewswire/ -- Alibaba Group Holding Limited (NYSE: BABA and HKEX: 9988 (HKD Counter) and 89988 (RMB Counter), "Alibaba" or "Alibaba Group")  recently announced findings from a new report highlighting Alibaba's positive impact on the U.S. economy and how its e-commerce platforms support U.S. businesses.
  • As such in 2022, $66.2 billion in sales from U.S. brands to Chinese consumers on Alibaba platforms helped to add $52.9 billion to the U.S.
  • Gross Domestic Product (GDP) and supported over 403,000 U.S. jobs, according to the report compiled by NDP Analytics and commissioned by Alibaba.
  • For more information on Alibaba and the report, please visit Alibabapowersbusinesses.com .